This channel is linked to the radiologic activities of Prof. Anwar Padhani. It contains video materials (some new, some old, some very old) of presentations, illustrative cases, and software that I think is interesting in prostate cancer imaging and next-generation imaging applications. Mostly, the talks are pitched at the post-graduate level and so can be complex/nuanced. I try to keep away from basic talks since there is plenty of free material to tap into. Some of the content posted will be changed (taken offline) to be replaced/updated by more refined or better illustrative material. Generally, I post on this channel before I tweet it out so subscribers get a heads-up first. A lot of stuff is my thoughts about where we are and are headed, but it may be subsequently shown to be totally wrong or more nuanced than I thought at the time - I hope that you will learn something from the contents. Thank you for listening and subscribing. Cheers.
My husband's prostate enlarged in size measures 46x45x43 mm and volume 44g.ADC value measures appox. 0.6 to 0.7 x 10-3 mm2/s. Study reveals small focal areas of diffusion restriction in the lower mid gland and apical region of the transition zone representing PIRADS-3 lesion. There are PIRADS -2 nodules in the transitional zone bilaterally as prescribed. Please suggest, how should we go for further action?
Hello Dr Anwar in your previous comments you mentioned that you use Simens AI software and Lucida as well Can you please explain me why would u need both the softwares Any reason to do so Thanks
We follow the clinical routine.. breast usually 3 monthly because serum markers are poor. In mHSPC we follow the PSA and review at baseline. Nadir and before next Rx start.. in mCRPC we switch to 3/12 because PSA becomes disconnected from tumour volume
Thanks for this unique information. I am looking forward the new version of PI-QUAL system, because it is really help me to say urologist about their patient's mri quality. I am agree with your idea about US certification and accreditation, it is really help everybody to improve the quality of mri and reports. It is sound sad, but i can trust only a few center of MRi in Russia, who make high quality multiparametric MRI. And another hospitals can do what they can (pi-qual 2-3) and use PI-RADS2.1 for their reports. It is the main idea why i can not work with different hospital in my country. But you should know that we follow your advices, thanks again.
Which study design is able to show that a new diagnostic modality is helpful while excluding/minimizing the probability of Will-Rogers effect, lead-time and length-time bias?
Very thought-provoking classification. 👏 Had to see the video twice! One Question: 🤔 If cancer cells first manipulate the osteoclasts and the progenitors of fibroblasts are the same as osteoblasts, is it correct to say that the early phase of marrow involvement for metastatic prostate cancer would be like this: PSMA-PET: + Bone scan: - FDG-PET: + (osteoclastic phase, if agressive phenotype and high GG) FAPI-PET: - (my main question) WB-MRI: -/+ (not hypercellular yet, similar to osteoclastic-only activity in the fat-predominant phenotype) CT: mildly hypodense, yet not lytic
You are better any AI. Thanks for the info, because I have no opportunity to read your article about screening in the European radiology(( and this is a big problem for doctors from Russia. I would like to ask you about PSA density in mri screening, maybe it can to increase sensitivity of this way?
Wow!!!👍🎩👍 Excellent presentation!! Really gonna help me in my decision making, in my possible diagnosis of prostate cancer, from my MRI. 3 Lesions......Pi-rads 4/5 But, my PSA, is only 2.5 How weird is that? Urologist right away, wants to do a traditional systematic 12 core biopsy. I may want to shoot for the MRI targeted focused biopsy instead. Less cores, less pain hopefully😅
Excellent video. One thing AI will do is it doesn't get burnt out. I read somewhere the greatest error comes from pathology inaccurately identifying the lesion.
This is an excellent lecture: a step-by-step guidance through the difficulties of prostate cancer screening and the beneficial role of the MRI-centered pathway. fully evidence-based with references to the latest literature.... a 40+ min journey... not a single minute to miss! thank you!
What would you say to someone who has a clearly detected bacterial prostatitis (through semen culture), a fluctuating PSA between 25 to 40 (after starting and stopping antibiotic treatment) and a small lesion (PIRADS 4, <1.5cm) in the TZ region detected by MpMRI (and similar vague readings on a PSMA PET scan)? Frustrating to find no detailed analysis anywhere of a situation when a single localised lesion is found along with AMR prostatitis. A biopsy could lead to sepsis so very hesitant to go that way.
Excellent and informative video. I had two prostate biopsies, four years apart. The first was random and was negative. Also, several DREs, even by different doctors were negative. Due to my rising PSA, my doctor recommended an MRI which identified a significant anomaly outside the reach of the DRE. A second biopsy, this time MRI targeted, was positive for cancer. I'm grateful my doctor recommended an MRI. I had no symptoms, and yet, cancer was already in the final stage before breaching my prostate.
I am sorry to hear about the delays in diagnosis. Hopefully it will happen less and less as knowledge spreads around the world. We continue to push the field forward as you can see by the videos that I have posted on the channel...
